Genomic Vision (Germany) Today
| G09 Stock | EUR 707.37 3.80 0.53% |
Performance2 of 100
| Odds Of DistressLess than 27
|
Genomic Vision is trading at 707.37 as of the 28th of November 2024. This is a 0.53 percent decrease since the beginning of the trading day. The stock's lowest day price was 706.44. Genomic Vision has about a 27 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Genomic Vision Socit are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 30th of August 2024 and ending today, the 28th of November 2024. Click here to learn more.
Genomic Vision Socit Anonyme, a molecular diagnostics and technology company, engages in the development of single DNA detection tools for research and in vitro diagnostics in France. The company was founded in 2004 and is headquartered in Bagneux, France. The company has 99.31 M outstanding shares. More on Genomic Vision Socit
Moving against Genomic Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Genomic Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Genomic Vision's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Genomic Vision or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Chairman | Aaron Bensimon |
| Business Concentration | Diagnostics & Research, Healthcare (View all Sectors) |
Genomic Vision Socit (G09) is traded on Frankfurt Exchange in Germany and employs 33 people. The company currently falls under 'Nano-Cap' category with a current market capitalization of 4.72 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Genomic Vision's market, we take the total number of its shares issued and multiply it by Genomic Vision's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Genomic Vision Socit classifies itself under Healthcare sector and is part of Diagnostics & Research industry. The entity has 99.31 M outstanding shares.
Genomic Vision Socit has accumulated about 2.94 M in cash with (4.52 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.06.
Check Genomic Vision Probability Of Bankruptcy
Ownership AllocationGenomic Vision Socit has a total of 99.31 Million outstanding shares. Genomic Vision retains 6.79 (percent) of its outstanding shares held by insiders and 4.04 (percent) owned by outside corporations. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Genomic Ownership Details
Genomic Vision Socit Risk Profiles
Although Genomic Vision's alpha and beta are two of the key measurements used to evaluate Genomic Vision's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 0.878 | |||
| Semi Deviation | 1.17 | |||
| Standard Deviation | 1.18 | |||
| Variance | 1.4 |
Genomic Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Genomic Vision without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Rebalancing Now
Portfolio RebalancingAnalyze risk-adjusted returns against different time horizons to find asset-allocation targets |
| All Next | Launch Module |
Genomic Vision Corporate Management
Elected by the shareholders, the Genomic Vision's board of directors comprises two types of representatives: Genomic Vision inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Genomic. The board's role is to monitor Genomic Vision's management team and ensure that shareholders' interests are well served. Genomic Vision's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Genomic Vision's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Emilie Chataignier | Member Board | Profile | |
| Beth Jacobs | Independent Member of the Supervisory Board | Profile | |
| Isabelle Racamier | Independent Chairman of the Supervisory Board | Profile | |
| Tamar Saraga | Independent Member of the Supervisory Board | Profile | |
| Stephane Verdood | Member of the Supervisory Board | Profile | |
| Elisabeth Ourliac | Independent Vice Chairwoman of the Supervisory Board | Profile |
Other Information on Investing in Genomic Stock
Genomic Vision financial ratios help investors to determine whether Genomic Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Genomic with respect to the benefits of owning Genomic Vision security.